anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a muscular soreness relieving and massaging cream and a preparing method thereof. The muscular soreness relieving and massaging cream is prepared from various bioactive constituents including chavicol methylether, matricaria azulene, alpha-bisabol, sesquiterpene lactone, menthol, menthone, citral and the like. The muscular soreness relieving and massaging cream has the main effect of rejuvenating the musculoskeletal system, and has the functions of diminishing inflammation, relieving pain, recovering muscles, the brain, the heart and the elasticity of the skin and the like. The muscular soreness relieving and massaging cream is suitable for rheumatism, arthritis and muscular soreness. Essential oil of the muscular soreness relieving and massaging cream is prepared from essence extracted from plants, and is natural, organic, free of any artificially-synthesized constituent, free of removal of any original constituent, free of decloration, free of rectification and free of over oxidation. Thus, the muscular soreness relieving and massaging cream is free of toxic or side effects on the human body. In addition, due to the fact that chemical molecules are small and are lipid soluble molecules, the muscular soreness relieving and massaging cream can quickly seep into the corium layer or the blood capillary of the skin, and has the advantage of being fast in absorption. When the muscular soreness relieving and massaging cream is used, the skin is fine, moist and smooth. The product is convenient to carry and use and applicable to a wide range of objects.
PURPOSE: Acute macular neuroretinopathy (AMN) can cause sudden-onset and permanent scotoma in healthy young patients. Analysis of optical coherence tomography (OCT) and OCT angiography (OCTA) of AMN patients may provide insights into disease mechanism.
METHODS: We conducted a retrospective study of consecutive SARS-Cov-2-related AMN patients that presented in our clinic between Jan 1st, 2022, and April 30th, 2023, within 30 days of symptom onset. Retinal vessel area density (VAD) of AMN lesions in OCTA was quantified and compared to an adjacent tissue control (ATC). This quantification was performed for the superficial vascular plexus (SVP), the intermediate capillary plexus (ICP), the deep capillary plexus (DCP), the choriocapillaris (CC), and choroid. Furthermore, en face OCT images were analyzed.
RESULTS: Nine AMN patients were identified, 6 of these (4 female, 2 male, average age 25 years) fulfilled the inclusion criteria and were included into this study. Average time from symptom onset to OCTA was 14.3 days. No VAD differences between AMN and adjacent tissue were found in either retinal layer (SVP, ICP, DCP). In contrast, VAD in CC was reduced by 27% against the ATC (p = 0.007) and choroidal VAD was reduced by 41% (p = 0.017). Further analysis of en face OCT could show that the pathognomonic infrared hyporeflectivity in AMN is caused by photoreceptor alterations rather than changes in the inner retinal layers.
CONCLUSIONS: Our data suggests that a perfusion deficit in the choroidal layers is responsible for AMN rather than in the DCP, which is the predominant hypothesis in current literature.
DIANEAL peritoneal dialysis solutions are sterile, nonpyrogenic solutions in flexible containers for intraperitoneal administration only. The peritoneal dialysis solutions contain no bacteriostatic or antimicrobial agents.

DIANEAL solutions are hyperosmolar solutions.

The plastic container is fabricated from polyvinyl chloride (PVC Plastic). Exposure to temperatures above 25°C/77°F during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period. The amount of water that can permeate from inside the solution container into the overwrap is insufficient to affect the solution significantly.

Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g. di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million; however, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by cell culture toxicity studies.
The invention discloses an immunity-enhancing tricholoma matsutake and cornua cervi pantotrichum composition and a preparation method thereof. The invention relates to a method for extracting a cornua cervi pantotrichum extract and polysaccharide of tricholoma matsutake and a method for preparing an immunity-enhancing composition. The invention solves the problems of a conventional method which is low in rate on extracting cornua cervi pantotrichum active ingredients and polysaccharide of tricholoma matsutake, not high in activity and complex in production process. The cornua cervi pantotrichum, as a conventional rare traditional Chinese medicine, contains various physiological active substances and has such pharmacological actions as enhancing the immunity of a body, inhibiting the activity of monoamine oxidase, resisting aging, resisting oxidation and the like. The tricholoma matsutake has a quite high medicinal value and has curative effects of strengthening body, tonifying stomach and intestines, treating diabetes, enhancing the immunity of the body and the like. The cornua cervi pantotrichum extract and the tricholoma matsutake polysaccharide extract are obtained from fresh cornua cervi pantotrichum and tricholoma matsutake through such modern technologies as vacuum freezing, ultrafine grinding, microwave-assisted extracting and the like, and the natural immunity-enhancing composition, which is prepared by reasonably combining the cornua cervi pantotrichum extract and the tricholoma matsutake polysaccharide extract, is free from any toxic and side effects. The composition has an excellent function of enhancing the immunity.
FE 999049 was administered as single daily subcutaneous injections in the abdomen. Participants randomized to FE 999049 had their individual dose determined on the basis of their anti-Müllerian hormone (AMH) level at screening and their body weight at randomization. The daily FE 999049 dose was fixed throughout the stimulation period. The minimum allowed daily FE 999049 dose was 6 μg and maximum allowed daily dose was 12 μg. Dosing continued until the criterion for triggering of final follicular maturation was met. Participants could be treated for a maximum of 20 days.
Behavioral: Behavior activation/BA plus T-RAC Each session is focused on reviewing the activity log, planning anti-depressant activities for the next week, and finding support for the implementation of the activity. After activity planning, the participants will follow an XboxKinect exergame for 10 minutes, an actfulness exercise and will imagine one planned activity using dynamic imagery. From session 2 restructuring action memories are added.
This is two center study was carried out on 523 patients and completed in 436 patients with gall bladder stones and with suspected or confirmed CBDS at two gastroenterology center at zagazig first 264 patients at the Gastrointestinal Surgery Unit in the Zagazig University Hospitals and second 172 patients at gastroenterology unite at AL AHRAR hospital from January 2010 till April 2022. A single-step technique combining LC and IO-ERCP was used to treat them. To confirm the presence of CBDS, a laparoscopic intraoperative cholangiography (IOC) was performed. A soft-tipped guidewire was inserted into the duodenum through the cystic duct and papilla. Over the guide-wire, an endoscopic papillotomy was introduced. The stones were retrieved with a retrieval balloon after an IO-ERCP and endoscopic sphincterotomy. The length of the postoperative hospital stay, surgical operating time, surgical success rate, postoperative complications, and residual CBDS were all evaluated. 77 patients excluded either incomplete data or didn't complete both steps within our centers.
In vitro and animal studies show that loperamide hydrochloride acts by slowing intestinal motility and by affecting water and electrolyte movement through the bowel. Loperamide binds to the opiate receptor in the gut wall. Consequently, it inhibits the release of acetylcholine and prostaglandins, thereby reducing peristalsis, and increasing intestinal transit time. Loperamide increases the tone of the anal sphincter, thereby reducing incontinence and urgency. 

In man, loperamide hydrochloride prolongs the transit time of the intestinal contents. It reduces the daily fecal volume, increases the viscosity and bulk density, and diminishes the loss of fluid and electrolytes. Tolerance to the antidiarrheal effect has not been observed. Clinical studies have indicated that the apparent elimination half-life of loperamide hydrochloride in man is 10.8 hours with a range of 9.1 to 14.4 hours. Plasma levels of unchanged drug remain below 2 nanograms per mL after the intake of a 2 mg loperamide hydrochloride capsule. Plasma levels are highest approximately five hours after administration of the capsule and 2.5 hours after the liquid. The peak plasma levels of loperamide were similar for both formulations. Elimination of loperamide mainly occurs by oxidative N-demethylation. Cytochrome P450 (CYP450) isozymes, CYP2C8 and CYP3A4, are thought to play an important role in loperamide N-demethylation process since quercetin (CYP2C8 inhibitor) and ketoconazole (CYP3A4 inhibitor) significantly inhibited the N-demethylation process in vitro by 40% and 90%, respectively. In addition, CYP2B6 and CYP2D6 appear to play a minor role in loperamide N-demethylation. Excretion of the unchanged loperamide and its metabolites mainly occurs through the feces. In those patients in whom biochemical and hematological parameters were monitored during clinical trials, no trends toward abnormality during loperamide hydrochloride therapy were noted. Similarly, urinalyses, EKG and clinical ophthalmological examinations did not show trends toward abnormality.
PURPOSE:To easily dehydrate a starfish with hot oil in high efficiency while preventing the loss of active component such as saponin and the dissolution of starfish by dehydrating a starfish using a hot oil as a thermal medium under two-stage evacuation process, comprising a former low-evacuation stage and a latter high-evacuation stage, and removing the oil from the dehydrated product. CONSTITUTION:A starfish is charged to a hot oil such as animal oil, fish oil or vegetable oil preheated in a cooker. The starfish is heated under stirring using the above hot oil as a thermal medium in two evacuation stages comprising the former lowevacuation stage to facilitate the coagulation of protein and the latter high- evacuation stage. The water-soluble protein and gelatin of the starfish are coagulated and stabilized in the former stage to prevent the dissolution loss of the active component of the starfish such as saponin. In the latter stage, the hot oil is impregnated into the cavity of the cell tissue left after the removal of water to effect the complete dehydration treatment. The dehydrated starfish is taken out of the cooker and the oil is removed from the product to obtain the objective starfish dehydrated with hot oil and sufficiently keeping the effect of the above component as a carcinostatic agent or vermin repellent.
Participants from birth (≤32 weeks gestation, 7 days postnatal) to \<3 months of age with creatinine clearance =20 - 49 mL/min/1.73 m\^2 received a single dose of TOL/TAZ 12/6 mg/kg as a 60-minute infusion on Day 1; participants with creatinine clearance ≥50 mL/min/1.73 m\^2 received a single dose of TOL/TAZ 20/10 mg/kg as a 60-minute infusion on Day 1. After interim analysis for Cohort 4, the original regimen of TOL/TAZ 12/6 was changed to TOL/TAZ 20/10 mg/kg for participants with creatinine clearance ≥50 mL/min/1.73 m\^2.
Maitland group, III. degree talus mobilization technique was applied. In this mobilization technique, 120 seconds of application, 60 seconds of rest, and then 120 seconds of application were performed. Maitland III, which takes 5 minutes in total. For the 10-degree mobilization technique, the participant was placed on his back with the foot pointing forward, the ankle was placed in 20° plantar flexion, and the talocrural ligament was in a relaxed position. The hand stabilizing the foot was placed proximal to the malleolus to stabilize the leg. The other hand performing the mobilization grasped the anterior talus using the first web space. The talus was then shifted posteriorly downwards with force.
NEW MATERIAL:A monoclonal antibody for nonglycosylated human interferon beta. USE:For quantitative analysis of nonglycosylated human interferon beta. PREPARATION:A mouse, etc. is immunized with a nonglycosylated human interferon beta, and splenic cells are prepared from the animal. Established cells obtained from the mouse are subjected to the subculture in 8-azaguanine culture medium, etc. and further in a normal culture medium to prepare myelomatous cells. On the other hand, the nonglycosylated human interferon beta is administered intraperitoneally to the immunized mouse, and the spleen is excised 3-4 days after the administration to prepare splenic cells. The resultant splenic cells and myelomatous cells are washed in Eagle's minimum essential medium (MEM culture medium), etc., and the splenic cells are mixed with the myelomatous cells. The resultant mixture is then centrifuged. The myelomatous cells are added to the precipitated cell groups, and the MEM culture medium is then added thereto. The mixture is further centrifuged to cultivate the resultant suspension. The resultant hybridoma cells capable of producing the monoclonal antibody for the nonglycosylated human interferon beta are intraperitoneally injected into a mouse to collect ascites, which are then dialyzed to afford the aimed monoclonal antibody.
Cholinergic degeneration is significant in Lewy body disease, including Parkinson's disease, dementia with Lewy bodies, and isolated REM sleep behaviour disorder. Extensive research has demonstrated cholinergic alterations in the CNS of these disorders. More recently, studies have revealed cholinergic denervation in organs that receive parasympathetic denervation. This enables a comprehensive review of cholinergic changes in Lewy body disease, encompassing both central and peripheral regions, various disease stages and diagnostic categories. Across studies, brain regions affected in Lewy body dementia show equal or greater levels of cholinergic impairment compared to the brain regions affected in Lewy body disease without dementia. This observation suggests a continuum of cholinergic alterations between these disorders. Patients without dementia exhibit relative sparing of limbic regions, whereas occipital and superior temporal regions appear to be affected to a similar extent in patients with and without dementia. This implies that posterior cholinergic cell groups in the basal forebrain are affected in the early stages of Lewy body disorders, while more anterior regions are typically affected later in the disease progression. The topographical changes observed in patients affected by comorbid Alzheimer pathology may reflect a combination of changes seen in pure forms of Lewy body disease and those seen in Alzheimer's disease. This suggests that Alzheimer co-pathology is important to understand cholinergic degeneration in Lewy body disease. Thalamic cholinergic innervation is more affected in Lewy body patients with dementia compared to those without dementia, and this may contribute to the distinct clinical presentations observed in these groups. In patients with Alzheimer's disease, the thalamus is variably affected, suggesting a different sequential involvement of cholinergic cell groups in Alzheimer's disease compared to Lewy body disease. Patients with isolated REM sleep behaviour disorder demonstrate cholinergic denervation in abdominal organs that receive parasympathetic innervation from the dorsal motor nucleus of the vagus, similar to patients who experienced this sleep disorder in their prodrome. This implies that REM sleep behaviour disorder is important for understanding peripheral cholinergic changes in both prodromal and manifest phases of Lewy body disease. In conclusion, cholinergic changes in Lewy body disease carry implications for understanding phenotypes and the influence of Alzheimer co-pathology, delineating subtypes and pathological spreading routes, and for developing tailored treatments targeting the cholinergic system.
Patients diagnosed with asthma by a chest diseases specialist and referred to pulmonary rehabilitation will be included in the study. The cases meeting the inclusion criteria will be randomized and divided into two groups, the groups will be named as High Intensity Inspiratory Muscle Training Group (H-IMT) and Low Intensity Inspiratory Muscle Training Group (L-IMT). Inspiratory muscle training will be carried out in the form of 2 minutes of work and 1 minute break for a total of 21 minutes, starting from 80% of the maximum inspiratory pressure determined by mouth pressure measurement for the H-IMT Group and 30% for the L-IMT Group. An 8-week training will be carried out by increasing the planned load by 5% every two weeks. In addition, breathing exercises, strengthening exercises and walking training on flat ground will be given to both groups in the form of a home program. The training program will be 8 weeks in total, 3 days a week. will be given online exercises, synchronized 2 days a week, and a home program for 1 day, accompanied by a physiotherapist, via videoconference on the smartphone. A total of 24 sessions will be held.
Patients receive high-dose melphalan IV over 30 minutes on days -2 and -1 and undergo autologous peripheral blood stem cell transplantation on day 0. Patients receive filgrastim IV or SC beginning on day 5 and continuing until blood counts recover. Beginning 4 to 8 weeks after transplantation, patients receive maintenance therapy comprising bortezomib IV on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive oral dexamethasone on days 1 to 4. Treatment with dexamethasone repeats every month for 12 months in the absence of disease progression or unacceptable toxicity. Beginning 2 weeks after completion of bortezomib, patients receive oral thalidomide once daily until disease progression.
The present invention provides a video signal processing circuit. When the present invention processes video signals by which word information is inserted in each frame or each field, the present invention can eliminate the deviation between the feeding speed and the processing speed of signals, and does not disrupt the continuity of the word information, etc. The present invention is characterized in that the present invention comprises a frame memorizer, a frame synchronization unit and a processing unit, wherein the frame memorizer receives and stores additional information and all frames of digital video signals relevant to every frame at first speed. The frame synchronization unit reads out all frames of the digital video signals from the frame memorizer at second speed. The processing unit does not repeat the additional information under the condition that the frame synchronization unit repeatedly reads out the same frame of the digital video signals, and does not skips over the additional information under the condition that the frame synchronization unit skips over a certain frame of the digital video signals and reads out the digital video signals. Therefore, the additional information is relevant to the digital video signals read out by the frame synchronization unit.
Participants will receive a single oral tablet of darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination \[FDC\]) Treatment A (whole tablet) as reference in session 1 then Treatment B(split tablet) as test in session 2 followed by Treatment C (crushed tablet mixed in applesauce) as test in session 3 under fed conditions (standardized breakfast) on Day 1 of each treatment session. There will be a washout period of at least 7 days between consecutive drug intakes.
The invention provides a traditional Chinese medicinal composition for veterinary use. The traditional Chinese medicinal composition contains a Radix Astragali and Chinese angelica extract product which is prepared from 10-90 parts by weight of Radix Astragali and 10-90 parts by weight of Chinese angelica. The traditional Chinese medicinal composition for veterinary use can be used for preventing and curing livestock viral diseases and has characteristics of high efficiency and low toxicity. The traditional Chinese medicinal composition for veterinary use can be combined with a vaccine for livestock, so as to raise the immune effect of the vaccine. Through the combined application method, treatment effect also can be enhanced. The traditional Chinese medicinal composition for veterinary use has advantages of simple preparation method and low cost. The prepared preparation product requires small dose and is convenient to store, carry and use.
In general, the present invention relates to epidermal lipoxygenase obtained from axolotl and pharmaceutical compositions containing the same. In particular, in a first aspect the present invention relates to pharmaceutical compositions containing lipoxygenase obtained from axolotl or functional homologues thereof having a lipoxygenase activity, in particular for use in wound healing, bone healing or conditioning of injured tissue, e.g. in wound dressings. In a further aspect, the present inventions relates to cosmetical compositions containing said lipoxygenase. Finally, the present invention provides methods for identifying modulators of wound healing, scarring, etc. comprising the step of determining compounds able to alterate the lipoxygenase enzyme activity.
The prepn. of natural and/or synthetic carbonate, esp. calcium carbonates with high specific surface greater than 20 (esp. 20-50) mc/g according to BET/N2 comprises wet grinding using known mills, esp. an agitated ball mill, in a cycle ie., with recycling the prod. leaving the mill back to the mill as often as is necessary to achieve a final prod. with the desired specific surface and ensuring that the solids concn. during the entire process of wet grinding is less than or equal to 24 wt. %.
Processed SFN-rich extract will be purchased from Nutramax Laboratories, Inc. 2208 Lakeside Blvd Edgewood, MD 21040. Caplets containing SFN-rich broccoli sprout extracts will be obtained from Nutramax Labs. Study medication will be dispensed in sealed bottles with instructions to keep them in a household freezer. The size of the caplet will be about the size of a 1000 mg Vit C pill (about 2 cm in length). The participants will be dosed, based on weight, in a double-blind fashion with identical appearing placebo or SFN caplets. Participants will be instructed to take a daily dose for 24 weeks based on the participants weight. Two caplets for individuals \<100 lb., three caplets for individuals 100-200 lb. and four caplets for individuals \>200 lb. SFN (Avmacol Extra Strength) will be prescribed by a study physician, and will be dispensed by the study coordinators at TTUHSC Lubbock. Pill counts will be conducted to demonstrate compliance.
A drug depot delivery system includes a housing having a cavity. A cartridge is positioned within the cavity and includes a body having a channel. The body includes a first pair of rails and a second pair of rails. A plunger is slidably disposed in the housing and the cartridge. The plunger is configured to move a drug depot through the channel and out of the housing. Kits and methods of use are disclosed.